Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low‐dose dasatinib therapy

Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia... Dear Editor,Tyrosine kinase inhibitors (TKI) are beneficially used for patients with breakpoint cluster region‐abelson (BCR‐ABL) fusion gene‐positive chronic myeloid leukemia (CML); however, elderly patients have a lower tolerance to the standard dose of TKI because of severe adverse events, and therefore a dose reduction or discontinuation of treatment is often required. Recently, low‐dose dasatinib (a dose as low as 20 mg/day) has been shown to be more effective than low‐dose imatinib. We have also reported a similar finding in an elderly chronic phase CML (CML‐CP) patient receiving low‐dose dasatinib (mean dose 5.7 mg/day). In the case of low‐dose therapy, a study of pharmacokinetics and pharmacodynamics is useful to determine the appropriate dosing for a preferable effect without severe adverse events. Although routine monitoring of the therapeutic plasma concentration should be carried out specifically in treatment‐resistant cases for avoiding unnecessary dose escalation, this can also be applied to patients who cannot receive the standard dose because of adverse events. It is controversial whether the trough or the peak concentration relates to a better outcome in the case of imatinib therapy. Regarding dasatinib, this kind of study was limited, and analysis of the intracellular concentration was also shown to be important http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Geriatrics & Gerontology International Wiley

Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low‐dose dasatinib therapy

Loading next page...
 
/lp/wiley/plasma-and-intracellular-concentrations-in-an-elderly-patient-with-P7SrvGrxOT
Publisher
Wiley
Copyright
© 2018 Japan Geriatrics Society
ISSN
1444-1586
eISSN
1447-0594
D.O.I.
10.1111/ggi.13238
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,Tyrosine kinase inhibitors (TKI) are beneficially used for patients with breakpoint cluster region‐abelson (BCR‐ABL) fusion gene‐positive chronic myeloid leukemia (CML); however, elderly patients have a lower tolerance to the standard dose of TKI because of severe adverse events, and therefore a dose reduction or discontinuation of treatment is often required. Recently, low‐dose dasatinib (a dose as low as 20 mg/day) has been shown to be more effective than low‐dose imatinib. We have also reported a similar finding in an elderly chronic phase CML (CML‐CP) patient receiving low‐dose dasatinib (mean dose 5.7 mg/day). In the case of low‐dose therapy, a study of pharmacokinetics and pharmacodynamics is useful to determine the appropriate dosing for a preferable effect without severe adverse events. Although routine monitoring of the therapeutic plasma concentration should be carried out specifically in treatment‐resistant cases for avoiding unnecessary dose escalation, this can also be applied to patients who cannot receive the standard dose because of adverse events. It is controversial whether the trough or the peak concentration relates to a better outcome in the case of imatinib therapy. Regarding dasatinib, this kind of study was limited, and analysis of the intracellular concentration was also shown to be important

Journal

Geriatrics & Gerontology InternationalWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off